Reply to the letter to the editor 'the harms of low-dose aspirin prophylaxis are overstated' by P. Elwood and G. Morgan

Affiliations

¹ Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK.
² Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK j.cuzick@qmul.ac.uk.

Free article

Comment

M A Thorat et al. Ann Oncol. 2015 Feb.

Free article

. 2015 Feb;26(2):442-3.

doi: 10.1093/annonc/mdu546. Epub 2014 Nov 17.

¹ Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK.
² Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK j.cuzick@qmul.ac.uk.

No abstract available

Comment on

Estimates of benefits and harms of prophylactic use of aspirin in the general population.
Cuzick J, Thorat MA, Bosetti C, Brown PH, Burn J, Cook NR, Ford LG, Jacobs EJ, Jankowski JA, La Vecchia C, Law M, Meyskens F, Rothwell PM, Senn HJ, Umar A. Cuzick J, et al. Ann Oncol. 2015 Jan;26(1):47-57. doi: 10.1093/annonc/mdu225. Epub 2014 Aug 5. Ann Oncol. 2015. PMID: 25096604 Free PMC article. Review.
The harms of low-dose aspirin prophylaxis are overstated.
Elwood P, Morgan G. Elwood P, et al. Ann Oncol. 2015 Feb;26(2):441-2. doi: 10.1093/annonc/mdu538. Epub 2014 Nov 21. Ann Oncol. 2015. PMID: 25416686 No abstract available.